Group 1 - The chemical pharmaceutical sector increased by 0.25% on November 3, with Asia-Pacific Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] - Asia-Pacific Pharmaceutical's stock price rose by 9.96% to 8.72, with a trading volume of 1.6689 million shares and a transaction value of 1.442 billion [1] Group 2 - The top gainers in the chemical pharmaceutical sector included HaiXiang Pharmaceutical, which rose by 9.93% to 6.31, and Tonghua Golden Horse, which increased by 8.37% to 28.10 [1] - The sector experienced a net outflow of 114 million from institutional investors, while retail investors saw a net outflow of 186 million, and speculative funds had a net inflow of 301 million [2][3] - The stock of YiPinHong decreased by 5.15% to 53.06, with a trading volume of 134,400 shares and a transaction value of 713 million [2]

Core Insights - The monkeypox concept stock increased by 3.20%, ranking 10th among concept sectors, with 69 stocks rising, including notable gainers like Zhongsheng Pharmaceutical and HeFu China, which hit the daily limit [1][2] - The sector saw a net inflow of 1.062 billion yuan, with 46 stocks receiving inflows, and five stocks attracting over 50 million yuan each, led by Zhongsheng Pharmaceutical with a net inflow of 305 million yuan [2][3] Stock Performance - Top gainers in the monkeypox sector included: - Zhongsheng Pharmaceutical: +10.02% with a turnover rate of 10.14% and a net inflow of 304.73 million yuan [3][4] - Asia-Pacific Pharmaceutical: +9.99% with a turnover rate of 21.34% and a net inflow of 258.69 million yuan [3][4] - Other notable performers included Yipin Hong (+9.94%) and Toukeng Life (+8.81%) [1][4] - Decliners in the sector included: - Kefu Medical: -4.35% - *ST Suwu: -1.98% - Jianfeng Group: -1.81% [1][6] Fund Flow Analysis - The top three stocks by net inflow ratio were: - Asia-Pacific Pharmaceutical: 21.24% - Zhongsheng Pharmaceutical: 20.95% - Hainan Hai Pharmaceutical: 16.73% [3][4] - The overall fund flow into the monkeypox concept was significant, indicating strong investor interest [2][3]

Core Insights - The chemical pharmaceutical sector experienced a significant increase of 3.77% on October 31, with Shutaishen leading the gains [1] - In contrast, the Shanghai Composite Index closed at 3954.79, down 0.81%, and the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Shutaishen (300204) with a closing price of 38.30, up 19.99% on a trading volume of 680,900 shares [1] - Kangla Pharmaceutical (300086) closed at 8.74, up 17.47% with a trading volume of 1,481,300 shares [1] - Zema Pharmaceutical (688266) closed at 103.88, up 16.14% on a trading volume of 93,300 shares [1] - Other significant performers included Yifang Bio (688382) up 15.30%, and Deyuan Pharmaceutical (920735) up 13.09% [1] Capital Flow - The chemical pharmaceutical sector saw a net inflow of 2.785 billion yuan from institutional investors, while retail investors experienced a net outflow of 974 million yuan [2] - The main stocks with significant capital inflow included: - Shutaishen with a net inflow of 472 million yuan, accounting for 19.44% of its trading volume [3] - Lianhuan Pharmaceutical (600513) with a net inflow of 338 million yuan, representing 39.88% of its trading volume [3] - Guangshengtang (300436) with a net inflow of 303 million yuan, making up 11.37% of its trading volume [3]

Core Viewpoint - Zhejiang Apac Pharmaceutical Co., Ltd. has announced its participation in the national centralized drug procurement, with its injectable Cefoperazone Sodium (1.0g) expected to be selected in this round of procurement [1] Group 1: Procurement Announcement - The 11th batch of national drug centralized procurement includes 55 types of drugs, covering common medications in various fields such as anti-infection, anti-allergy, anti-tumor, and more [1] - A total of 46,000 medical institutions participated in the bidding, with 445 companies submitting 794 products, and 272 companies having 453 products proposed for selection [1] Group 2: Product Information - Injectable Cefoperazone Sodium is a third-generation cephalosporin antibiotic with broad-spectrum antibacterial activity, suitable for various infections [1] - This product is one of the key offerings of Apac Pharmaceutical, projected to generate sales revenue of 13.6965 million yuan in 2024, accounting for 3.38% of the company's total revenue [1] Group 3: Future Prospects - If procurement contracts are signed and implemented, it will expand sales of related products, enhance market share, and improve brand influence, positively impacting future operating performance [2] - The company reported a revenue of approximately 228 million yuan and a net profit of about 97.2 million yuan for the first three quarters, marking a significant year-on-year increase of 2,909.49% [2] - The company is undergoing a change in actual control, with the chairman of Yaodou Technology set to become the new controlling shareholder, and plans to raise 700 million yuan for new drug research and development [2] - The market anticipates that the company will continue to focus on innovation and transformation towards innovative drugs, with "industry synergy + innovation-driven" becoming a core focus for the future [2]

2024年，公司拟中选品种的销售情况如下： 1 产品名称 适应症 规格 拟 中 选 价 格（元/瓶） 拟主供省份 注射用头 孢唑肟钠 注射用头孢唑肟钠属于第三代头孢菌素类抗生 素，具有广谱抗菌作用，适用于敏感菌所致的下 呼吸道感染、尿路感染、腹腔感染、盆腔感染、 败血症、皮肤软组织感染、骨和关节感染、肺炎 链球菌或流感嗜血杆菌所致脑膜炎和单纯性淋 病。 1.0g 3.65 福建、重庆、 江西 一、拟中选产品的基本情况 证券代码：002370 证券简称：亚太药业 公告编号：2025-089 浙江亚太药业股份有限公司 关于公司参与全国药品集中采购拟中选的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不 存在虚假记载、误导性陈述或者重大遗漏。 浙江亚太药业股份有限公司（以下简称"亚太药业"或"公司"） 于近日参加了国家组织药品联合采购办公室（以下简称"联采办"） 组织开展的第十一批全国药品集中采购的投标工作，公司产品注射用 头孢唑肟钠拟中选本次集中采购，现将相关情况公告如下： 注：1、上述产品的拟中选价格等信息以联采办发布的最终结果为准。 2、根据相关规定，本次拟中选产品的采购周期自中选结果执行之日起至 ...

杭州市上城区新业路 8 号华联时代大厦 B 幢 22 层 电话：0571-88362156 传真：0571-88362156 邮编：310016 北京国枫（杭州）律师事务所 关于浙江亚太药业股份有限公司 2025 年第二次临时股东大会的 法律意见书 国枫律股字[2025]G0019 号 致：浙江亚太药业股份有限公司（贵公司） 北京国枫（杭州）律师事务所（以下称"本所"）接受贵公司的委托，指派律师出席 并见证贵公司2025年第二次临时股东大会（以下称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下称《公司法》）《中华人民共和国证 券法》（以下称《证券法》）《上市公司股东会规则》（以下称《股东会规则》）《律师事务 所从事证券法律业务管理办法》（以下称《证券法律业务管理办法》）及《律师事务所证 券法律业务执业规则（试行）》（以下称《证券法律业务执业规则》）等相关法律、行政 法规、规章、规范性文件及《浙江亚太药业股份有限公司章程》（以下称《公司章程》） 的规定，就本次会议的召集与召开程序、召集人资格、出席会议人员资格、会议表决程 序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如 ...

证券代码：002370 证券简称：亚太药业 公告编号：2025-088 浙江亚太药业股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 现场会议召开时间：2025 年 10 月 29 日下午 14：00 网络投票时间： 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025年 10月29日上午9:15—9:25，9:30－11:30，下午13:00－15:00； 通 过 深 圳 证 券 交 易 所 互 联 网 投 票 系 统 （http://wltp.cninfo.com.cn）投票的具体时间为 2025 年 10 月 29 日上午 9：15 至下午 15：00 的任意时间。 2、现场会议召开地点：浙江省绍兴滨海新城沥海镇南滨西路 36 号公司办公楼三楼会议室 3、会议召集人：浙江亚太药业股份有限公司董事会。 4、会议召开方式：本次会议 ...

New Stock Issuance - Multiple companies are experiencing significant abnormal fluctuations in stock prices, including 香农芯创 (300475) with a notice date of 2025-10-24[1] - 天普股份 (605255) reported on 2025-10-21[1] - 生益电子 (688183) and 达华智能 (002512) both reported on 2025-10-29[1] Trading Alerts - 21 companies have been flagged for abnormal trading activities as of 2025-10-29, indicating potential volatility in the market[1] - ST新华锦 (600735) and 汇绿生态 (001267) are among those with recent alerts on 2025-10-29[1] - The report includes links to detailed announcements for each company, providing transparency and further information for investors[1] Market Trends - The report highlights a trend of increased scrutiny on companies with abnormal stock price movements, suggesting a potential shift in regulatory focus[1] - Investors are advised to monitor these stocks closely due to the heightened risk associated with abnormal fluctuations[1]

Core Viewpoint - Zhejiang Apac Pharmaceutical Co., Ltd. has reported significant growth in its third-quarter results, with a net profit increase of 2,909.49% year-on-year, indicating a strong operational performance and market expectations being met [1][2]. Financial Performance - For the first three quarters, the company achieved a revenue of 228,305,775.20 yuan and a net profit attributable to shareholders of 97,195,012.22 yuan [1]. - The third quarter alone saw revenues of 76,231,043.79 yuan, with a 47.69% increase in net profit after excluding non-recurring gains and losses [1]. - The net assets of the company reached 1.121 billion yuan, reflecting a 15.33% growth compared to the end of the previous year [2]. - Cash reserves exceeded 610 million yuan, indicating strong liquidity and financial resilience [2]. - The company has eliminated short-term borrowings and non-current liabilities due within one year, showcasing excellent short-term debt repayment capability [2]. Strategic Developments - The company announced a change in actual control, with Qiu Zhongxun, the chairman of Yaodou Technology, set to become the new controlling shareholder [1]. - A directed issuance of 700 million yuan will be made to the new controlling shareholder, with all funds allocated for new drug research and development, reflecting confidence in the company's transformation towards innovative drugs [1][4]. - The strategic focus on innovative drug development aligns with national policies supporting high-tech industries, positioning the company to capitalize on significant market opportunities [3][4]. Industry Context - The "14th Five-Year Plan" emphasizes the growth of high-tech industries, particularly in innovative pharmaceuticals, which are expected to benefit from strong policy support [3]. - The innovative drug sector is projected to experience rapid growth, with the number of clinical trial applications (INDs) reaching 428, a 35% increase year-on-year, and the total value of domestic innovative drug licensing transactions exceeding 20 billion USD [3]. Innovation and R&D Focus - The company plans to invest in oncolytic virus drug development and long-acting formulations, targeting multiple innovative drug pipelines [4]. - The market for related anti-tumor biological drugs is expected to reach approximately 160 billion yuan in China and the U.S. by 2025, indicating a promising market outlook [4]. Synergy and Business Model - The integration of traditional pharmaceutical operations with innovative drug development is seen as a complementary relationship, where stable cash flow from traditional products supports high investment in R&D [6]. - The company holds 114 approved drug formulations, with over half being antibiotics, providing a solid cash flow foundation for future innovations [6]. - The new controlling shareholder's resources and the existing antibiotic business are expected to create synergies that enhance commercialization capabilities [6][7]. Market Positioning - The company is leveraging Yaodou Technology's extensive digital marketing network to enhance the distribution of its antibiotic products, particularly in grassroots medical institutions [7]. - This strategic positioning allows the company to respond effectively to market demand fluctuations, especially during peak seasons for respiratory diseases [7]. - The dual focus on maintaining traditional business stability while advancing into innovative drug development is viewed as a healthy transition strategy for the company [7].

证券日报网讯 10月28日晚间，亚太药业发布2025年第三季度报告称，2025年前三季度公司实现营业收 入228，305，775.20元，同比下降25.59%；归属于上市公司股东的净利润为97，195，012.22元，同比 增长2909.49%。 （文章来源：证券日报） ...